CNTA

Centessa Pharmaceuticals Stock Analysis

AI Rating

Low
  • Quality3/10
  • Growth↓ 0/10
  • Value↓ 0/10
Centessa Pharmaceuticals sales and earnings growth
CNTA Growth
Low
  • Revenue Y/Y↑ 118.88%
  • EPS Y/Y↓ -25.00%
  • FCF Y/Y↓ -38.97%
Centessa Pharmaceuticals gross and profit margin trends
CNTA Profitability
Neutral
  • Gross margin ↑ 100.00%
  • EPS margin↓ -1618.00%
  • ROIC 5Y↓ -95.75%
Centessa Pharmaceuticals net debt vs free cash flow
CNTA Risk
Great
  • Debt / Equity↓ 0.4
  • Debt / FCF↓ 0.4
  • Interest coverage↓ -20.5

Centessa Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗